Cencora, Inc. (COR) Debt to Equity Ratio: 7.13
Is Cencora, Inc.’s debt to equity ratio high or low?
Cencora, Inc.'s debt to equity ratio of 7.13 is 59% below its 4-year average of 17.42, near the low end of its 4-year range (7.13–39.18).
As of Saturday, June 13, 2026. 18.19% below its 12-month average of 8.71.
COR Debt to Equity Ratio Chart
COR Average Debt to Equity Ratio Chart
COR Current vs Average Debt to Equity Ratio Chart
COR Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
7.13
DEBT TO EQUITY RATIO AVG TTM
8.71
DEBT TO EQUITY RATIO AVG 3Y
10.16
DEBT TO EQUITY RATIO AVG 5Y
17.42
DEBT TO EQUITY RATIO AVG 10Y
9.20
DEBT TO EQUITY RATIO AVG 15Y
6.14
DEBT TO EQUITY RATIO AVG 20Y
4.62
CURRENT VS TTM AVG
-18.19%
CURRENT VS 3Y AVG
-29.85%
CURRENT VS 5Y AVG
-59.06%
CURRENT VS 10Y AVG
-22.53%
CURRENT VS 15Y AVG
+16.11%
CURRENT VS 20Y AVG
+54.43%
COR Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cencora, Inc. (COR) | $54.80B | 7.13 | 8.71 | 10.16 | 17.42 |
| Becton, Dickinson and Company (BDX) | $52.98B | 0.76 | 0.79 | 0.73 | 0.74 |
| Regeneron Pharmaceuticals, Inc. (REGN) | $63.06B | 0.09 | 0.09 | 0.10 | 0.13 |
| Humana Inc. (HUM) | $45.53B | 0.73 | 0.74 | 0.75 | 0.72 |
| IDEXX Laboratories, Inc. (IDXX) | $44.24B | 0.67 | 0.65 | 1.10 | 1.25 |
| Agilent Technologies, Inc. (A) | $36.67B | 0.50 | 0.55 | 0.53 | 0.52 |
| Zoetis Inc. (ZTS) | $33.36B | 2.85 | 2.13 | 1.86 | 1.81 |
| Centene Corporation (CNC) | $32.19B | 0.94 | 0.84 | 0.83 | 0.81 |
| Medline Inc. (MDLN) | $30.96B | 1.17 | 1.09 | 0.79 | 0.79 |
| Cigna Corporation (CI) | $78.83B | 0.75 | 0.77 | 0.73 | 0.72 |
Financial Health
Debt/Equity
7.13
Current Ratio
0.90
Cencora, Inc. Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Cencora, Inc. Debt to Equity Ratio FAQ
- What is the debt to equity ratio for Cencora, Inc. (COR)?
- The debt to equity ratio for COR stock is 7.13.
- Is Cencora, Inc.'s debt to equity ratio high or low?
- Cencora, Inc.'s debt to equity ratio of 7.13 is 59% below its 4-year average of 17.42, near the low end of its 4-year range (7.13–39.18).
- What is the TTM average debt to equity ratio for Cencora, Inc. (COR)?
- The TTM average debt to equity ratio for COR stock is 8.71.
- What is the 3Y average debt to equity ratio for Cencora, Inc. (COR)?
- The 3Y average debt to equity ratio for COR stock is 10.16.
- What is the 5Y average debt to equity ratio for Cencora, Inc. (COR)?
- The 5Y average debt to equity ratio for COR stock is 17.42.
- What is the 10Y average debt to equity ratio for Cencora, Inc. (COR)?
- The 10Y average debt to equity ratio for COR stock is 9.20.
- What is the 15Y average debt to equity ratio for Cencora, Inc. (COR)?
- The 15Y average debt to equity ratio for COR stock is 6.14.
- What is the 20Y average debt to equity ratio for Cencora, Inc. (COR)?
- The 20Y average debt to equity ratio for COR stock is 4.62.
Cencora, Inc. Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-09-30 | 7.13 |
| 2024-09-30 | 10.30 |
| 2023-09-30 | 13.06 |
| 2021-09-30 | 39.18 |
| 2019-09-30 | 1.56 |
| 2018-09-30 | 1.59 |
| 2017-09-30 | 1.84 |
| 2016-09-30 | 2.10 |
| 2015-09-30 | 6.07 |
| 2014-09-30 | 1.02 |
| 2013-09-30 | 0.60 |
| 2012-09-30 | 0.59 |
| 2011-09-30 | 0.48 |
| 2010-09-30 | 0.45 |
| 2009-09-30 | 0.43 |
| 2008-09-30 | 0.44 |
| 2007-09-30 | 0.40 |
| 2006-09-30 | 0.26 |
| 2005-09-30 | 0.22 |
| 2004-09-30 | 0.33 |
| 2003-09-30 | 0.45 |
| 2002-09-30 | 0.55 |
| 2001-09-30 | 0.56 |
| 2000-09-30 | 1.46 |
| 1999-09-30 | 3.36 |
| 1998-09-30 | 6.03 |
| 1997-09-30 | 41.24 |
Related Metrics
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Robert Mauch